PITTSBURGH--(BUSINESS WIRE)--A clinical study reporting an association between the results of the ChemoFx® chemoresponse assay and recurrence free survival (RFS) of cervical cancer patients has been accepted for publication by Gynecologic Oncology. Initial findings were presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) in Vancouver October 13-16, 2012.
“From a clinical standpoint, the additional information that ChemoFx provides informs clinicians when choosing an effective second line agent for the patient, with the ultimate goal of receiving maximum benefit.”
The independent study on the assay was conducted by Perry W. Grigsby, M.D., Professor of Radiation Oncology at the Washington University School of Medicine in St Louis, Missouri. Dr. Grigsby is known for his clinical research in gynecologic cancers and was most recently listed in America’s Top Doctors 2007-2012.
The study titled, In Vitro Chemoresponse to Cisplatin and Outcomes in Cervical Cancer, analyzedcervical cancer patients with stage Ib2 to IIIb disease who were treated with weekly cisplatin chemoradiation (chemoRT) and received pre-treatment cisplatin chemoresponse testing with ChemoFx.
Initial findings presented revealed the 2-year recurrence free survivals (RFS) for patients who scored as responsive or intermediately responsive to cisplatin via ChemoFx were 87%, compared to 58% for those who were scored as non-responsive to cisplatin (p = 0.047). This 50% increase in response clearly demonstrates the significant impact this assay could have on patient outcomes.
The data presented at IGCS concluded that the use of ChemoFx to perform a chemoresponse analysis of cervical cancer prior to treatment was predictive of RFS outcomes in patients treated with weekly cisplatin chemoRT. These results support the use of ChemoFx for helping with treatment decisions for cervical cancer patients.
“These data show a significant correlation between assay prediction of response and progression free interval,” says Dr. Perry W. Grigsby. “From a clinical standpoint, the additional information that ChemoFx provides informs clinicians when choosing an effective second line agent for the patient, with the ultimate goal of receiving maximum benefit.”
Cervical cancer is the third leading cause of average-years of life lost in the United States. The American Cancer Society (ACS) estimates there will be 12,340 new cases of invasive cervical cancer in the United States in 2013. More young women are contracting this devastating disease because of the spread of the human papillomavirus (HPV), with 21% of cervical cancer cases diagnosed in women aged 20–29 years. Worldwide, there are more than 400,000 new cases of cervical cancer diagnosed each year. Currently, no standard treatment is available for patients with recurrent cervical cancer that has spread beyond the confines of a radiation or surgical field.
ChemoFx® is a proprietary, CLIA-certified and commercially-available chemoresponse assay which measures an individual’s tumor response to a range of therapeutic alternatives under consideration by the treating physician. By testing multiple chemotherapies on a patient's tumor cells before treating a cancer patient, ChemoFx® helps determine the chemotherapies more likely to be effective and, therefore, provides valuable insights that help inform physicians' treatment decisions with a goal of improving patient outcomes.
Precision Therapeutics currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. Over 80,000 patient specimens to date have been tested with ChemoFx®.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s leading products for personalized cancer care include the ChemoFx® chemoresponse assay and BioSpeciFx®, a select portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. Additionally, in 2013 Precision plans to release two new gene signature products, under the GeneFx® brand. For more information, visit www.precisiontherapeutics.com or www.chemofx.com.